Physician profile
Timothy E Foley
NPI 1831147701
$10,734.45
in general payments reported to CMS, 2019-2025
40 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,108 · 2022: $2,180 · 2023: $2,298 · 2024: $2,275 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,445.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,885.69 | 2021-2025 | |
| Novo Nordisk INC | $1,375.56 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $961.72 | 2021-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $870.38 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $822.17 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $804.48 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $520.46 | 2021-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $442.47 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $388.28 | 2021-2024 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $376.73 | 2022-2024 | Jardiance |
| Lundbeck LLC | $300.20 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $225.95 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $220.60 | 2022-2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $194.95 | 2022 | |
| Exact Sciences Corporation | $144.24 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Foley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.